[시장보고서]컴피턴트 세포 시장 규모, 점유율, 동향 분석 : 유형별, 용도별, 최종 용도별, 지역별 전망 및 예측(2024-2031년)

컴피턴트 세포 시장 규모, 점유율, 동향 분석 : 유형별, 용도별, 최종 용도별, 지역별 전망 및 예측(2024-2031년)

Global Competent Cells Market Size, Share & Trends Analysis Report By Type, By Application (Cloning, Protein Expression, Mutagenesis, and Others), By End-Use, By Regional Outlook and Forecast, 2024 - 2031

상품코드 : 1522030 해당 상품은 즉시 배송 가능합니다

리서치사 : KBV Research

발행일 : 2024년 07월

페이지 정보 : 영문 237 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,600

￦ 5,241,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320

￦ 6,289,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048

￦ 8,805,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

세계 컴피턴트 세포 시장 규모는 예측 기간 동안 7.9%의 CAGR로 성장하여 2031년까지 37억 달러에 달할 것으로 예상됩니다.

또한, 이 세포는 관심 있는 유전자를 도입하고 발현시켜 그 기능을 연구하는 데 필수적입니다. 연구자들은 이 세포를 사용하여 특정 유전자를 복제하고, DNA 서열을 조작하고, 유전자 상호 작용을 조사합니다. 이는 생물학적 과정과 질병 메커니즘을 이해하는 데 필수적입니다. 따라서 유전체 연구와 단백질체 연구의 확대가 시장 성장을 촉진하고 있습니다.

또한, 팬데믹으로 인해 제약 및 생명공학 기업들이 백신 및 치료제 연구개발에 박차를 가하면서 세포에 대한 수요가 증가하였습니다. 또한, 유능한 세포 분야의 기업들은 공급망 중단을 방지하기 위해 신속하게 적응하여 팬데믹 기간 동안 시장의 안정성과 성장을 강화했습니다. 이처럼 COVID-19 팬데믹은 시장에 긍정적인 영향을 미쳤습니다.

그러나 역량 세포 생산 시설을 구축하기 위해서는 바이오리액터, 인큐베이터, 정제 시스템, 멸균 시설 등 전용 장비에 대한 막대한 투자가 필요합니다. 또한, 실험실 규모에서 상업적 규모로 생산을 확대하려면 공정 최적화, 검증 및 시설 확장과 관련된 추가 비용이 발생할 수 있습니다. 따라서 높은 초기 비용이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

유형별 전망

유형별로 시장은 화학적 유능한 셀, 전기적 유능한 셀, 슈퍼 유능한 셀로 나뉩니다. 전기적 유능한 셀 부문은 2023년 시장에서 34%의 매출 점유율을 차지했습니다. 전기적 유능세포는 일반적으로 화학적 유능세포에 비해 높은 형질전환 효율을 제공합니다. 따라서 유전자 편집, 라이브러리 구축, 하이스루풋 스크리닝 등 형질전환 효율을 정밀하게 제어해야 하는 응용 분야에 적합합니다.

용도 전망

용도별로 시장은 클론, 단백질 발현, 돌연변이 유발 및 기타로 분류되며, 2023년 단백질 발현 부문은 시장에서 24%의 매출 점유율을 차지했습니다. 높은 형질전환 효율과 강력한 단백질 발현 능력을 갖춘 이 세포는 대량의 재조합 단백질을 생산하는 데 적합합니다.

북미
- 북미의 컴피턴트 세포 시장 : 국가별
  - 미국
  - 캐나다
  - 멕시코
  - 기타 북미
유럽
- 유럽의 컴피턴트 세포 시장 : 국가별
  - 독일
  - 영국
  - 프랑스
  - 러시아
  - 스페인
  - 이탈리아
  - 기타 유럽
아시아태평양
- 아시아태평양의 컴피턴트 세포 시장 : 국가별
  - 중국
  - 일본
  - 인도
  - 한국
  - 호주
  - 말레이시아
  - 기타 아시아태평양
라틴아메리카, 중동 및 아프리카
- 라틴아메리카, 중동 및 아프리카의 컴피턴트 세포 시장 : 국가별
  - 브라질
  - 아르헨티나
  - 아랍에미리트
  - 사우디아라비아
  - 남아프리카공화국
  - 나이지리아
  - 기타 라틴아메리카, 중동 및 아프리카

제9장 기업 개요

Thermo Fisher Scientific, Inc
Merck KGaA
Agilent Technologies, Inc
Bio-Rad laboratories, Inc
Promega Corporation
New England Biolabs, Inc
Qiagen NV
F Hoffmann-La Roche Ltd.
Takara Bio Inc(Takara Holdings Inc.)
Lonza Group Ltd(Capsugel)

제10장 컴피턴트 세포 시장 성공 필수 조건

ksm

영문 목차

영문목차

The Global Competent Cells Market size is expected to reach $3.7 billion by 2031, rising at a market growth of 7.9% CAGR during the forecast period.

Rising healthcare expenditures in Asia Pacific countries fuel demand for innovative biopharmaceuticals, personalized medicine, and diagnostic tools. These cells are essential in developing these healthcare solutions, contributing to market growth. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.

Recombinant DNA technology is fundamental for cloning and expressing genes in host cells. These cells are essential for introducing recombinant DNA into bacterial cells to produce therapeutic proteins, enzymes, and vaccines. In addition, the development of personalized medicine, which tailors' treatments based on individual genetic profiles, relies on recombinant DNA technology and these cells. Hence, the growing demand for recombinant DNA technology drives the market's growth.

Additionally, these cells are essential for introducing and expressing genes of interest to study their functions. Researchers use these cells to clone specific genes, manipulate DNA sequences, and explore gene interactions, which are fundamental in understanding biological processes and disease mechanisms. Thus, the expansion of genomic and proteomic studies is propelling the market's growth.

Moreover, the pandemic spurred heightened demand for these cells as pharmaceutical and biotech companies accelerated research and development efforts for vaccines and therapies. Also, companies in the competent cells sector adapted quickly to ensure uninterrupted supply chains, enhancing market stability and growth during the pandemic. Thus, the COVID-19 pandemic had a positive impact on the market.

However, establishing a competent cell production facility requires significant investment in specialized equipment such as bioreactors, incubators, purification systems, and sterile facilities. Moreover, scaling up production from laboratory-scale to commercial quantities can involve additional costs related to process optimization, validation, and facility expansion. Hence, high initial costs are hindering the growth of the market.

Type Outlook

Based on type, the market is divided into chemically competent cells, electrocompetent cells, and ultracompetent cells. The electrocompetent cells segment attained 34% revenue share in the market in 2023. Electrocompetent cells typically offer higher transformation efficiencies compared to chemically competent cells. This makes them suitable for applications that require precise control over transformation efficiency, such as gene editing, library construction, and high-throughput screening.

Application Outlook

On the basis of application, the market is segmented into cloning, protein expression, mutagenesis, and others. In 2023, the protein expression segment attained a 24% revenue share in the market. These cells with high transformation efficiencies and robust protein expression capabilities are preferred for generating large quantities of recombinant proteins.

End-Use Outlook

By end-use, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and others. The academic & research institutes segment procured a 37% revenue share in the market in 2023. These cells are fundamental tools in molecular biology research for studying gene function, protein expression, and genetic pathways. Academic institutions use these cells to conduct basic research that advances our understanding of biological processes and diseases.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 35% revenue share in the market in 2023. North America hosts some of the world's leading biotechnology and pharmaceutical companies, particularly the United States and Canada. These industries drive substantial demand for these cells for research, development, and production of biopharmaceuticals, vaccines, and therapeutic proteins.

Recent Strategies Deployed in the Market

Jun-2024: Thermo Fisher Scientific established a new manufacturing practice (cGMP) facility in Bleiswijk, Netherlands, bolstering its European clinical trial capabilities for advanced therapies. The site offers comprehensive support for cell and gene therapies, emphasizing sustainable operations towards achieving net-zero emissions by 2050.
May-2024: Thermo Fisher Scientific launched the Applied Biosystems Axiom BloodGenomiX Array, designed for accurate blood genotyping in clinical research. This innovative platform covers over 40 genes and more than 260 antigens, detecting both HLA and HPA types with an impressive concordance rate of 99.89%.
Dec-2022: Agilent's Resolution ctDx FIRST has received FDA approval as a companion diagnostic for KRAS G12C mutations in advanced non-small cell lung cancer (NSCLC), facilitating treatment decisions for patients eligible for KRAZATI (adagrasib). Developed with Mirati Therapeutics, this liquid biopsy NGS assay offers broad genomic profiling for NSCLC patients.
Sep-2023: Thermo Fisher Scientific and the National Minority Quality Forum are partnering through ARC to improve access to clinical research for historically underserved communities. The collaboration aims to promote diversity in trials and facilitate equitable healthcare access initiatives.
Sep-2023: Thermo Fisher Scientific introduces the TSX Universal Series ULT Freezers, featuring enhanced performance, energy efficiency, and adaptability across lab settings. Certified by ENERGY STAR(R) and designed for sustainability, these freezers support diverse scientific workflows and stringent quality standards.

List of Key Companies Profiled

Thermo Fisher Scientific, Inc.
Merck KGaA
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Promega Corporation
New England Biolabs, Inc.
Qiagen N.V
F. Hoffmann-La Roche Ltd.
Takara Bio Inc. (Takara Holdings Inc.)
Lonza Group Ltd. (Capsugel)

Global Competent Cells Market Report Segmentation

By Type

Chemically Competent Cells
Electrocompetent Cells
Ultracompetent Cells

By Application

Cloning
Protein Expression
Mutagenesis
Others

By End-Use

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Global Competent Cells Market, by Type
- 1.4.2 Global Competent Cells Market, by Application
- 1.4.3 Global Competent Cells Market, by End-Use
- 1.4.4 Global Competent Cells Market, by Geography
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. Strategies Deployed in Competent Cells Market

Chapter 5. Global Competent Cells Market by Type

5.1 Global Chemically Competent Cells Market by Region
5.2 Global Electrocompetent Cells Market by Region
5.3 Global Ultracompetent Cells Market by Region

Chapter 6. Global Competent Cells Market by Application

6.1 Global Cloning Market by Region
6.2 Global Protein Expression Market by Region
6.3 Global Mutagenesis Market by Region
6.4 Global Others Market by Region

Chapter 7. Global Competent Cells Market by End-Use

7.1 Global Pharmaceutical & Biotechnology Companies Market by Region
7.2 Global Academic & Research Institutes Market by Region
7.3 Global Others Market by Region

Chapter 8. Global Competent Cells Market by Region

8.1 North America Competent Cells Market
- 8.1.1 North America Competent Cells Market by Type
  - 8.1.1.1 North America Chemically Competent Cells Market by Country
  - 8.1.1.2 North America Electrocompetent Cells Market by Country
  - 8.1.1.3 North America Ultracompetent Cells Market by Country
- 8.1.2 North America Competent Cells Market by Application
  - 8.1.2.1 North America Cloning Market by Country
  - 8.1.2.2 North America Protein Expression Market by Country
  - 8.1.2.3 North America Mutagenesis Market by Country
  - 8.1.2.4 North America Others Market by Country
- 8.1.3 North America Competent Cells Market by End-Use
  - 8.1.3.1 North America Pharmaceutical & Biotechnology Companies Market by Country
  - 8.1.3.2 North America Academic & Research Institutes Market by Country
  - 8.1.3.3 North America Others Market by Country
- 8.1.4 North America Competent Cells Market by Country
  - 8.1.4.1 US Competent Cells Market
    - 8.1.4.1.1 US Competent Cells Market by Type
    - 8.1.4.1.2 US Competent Cells Market by Application
    - 8.1.4.1.3 US Competent Cells Market by End-Use
  - 8.1.4.2 Canada Competent Cells Market
    - 8.1.4.2.1 Canada Competent Cells Market by Type
    - 8.1.4.2.2 Canada Competent Cells Market by Application
    - 8.1.4.2.3 Canada Competent Cells Market by End-Use
  - 8.1.4.3 Mexico Competent Cells Market
    - 8.1.4.3.1 Mexico Competent Cells Market by Type
    - 8.1.4.3.2 Mexico Competent Cells Market by Application
    - 8.1.4.3.3 Mexico Competent Cells Market by End-Use
  - 8.1.4.4 Rest of North America Competent Cells Market
    - 8.1.4.4.1 Rest of North America Competent Cells Market by Type
    - 8.1.4.4.2 Rest of North America Competent Cells Market by Application
    - 8.1.4.4.3 Rest of North America Competent Cells Market by End-Use
8.2 Europe Competent Cells Market
- 8.2.1 Europe Competent Cells Market by Type
  - 8.2.1.1 Europe Chemically Competent Cells Market by Country
  - 8.2.1.2 Europe Electrocompetent Cells Market by Country
  - 8.2.1.3 Europe Ultracompetent Cells Market by Country
- 8.2.2 Europe Competent Cells Market by Application
  - 8.2.2.1 Europe Cloning Market by Country
  - 8.2.2.2 Europe Protein Expression Market by Country
  - 8.2.2.3 Europe Mutagenesis Market by Country
  - 8.2.2.4 Europe Others Market by Country
- 8.2.3 Europe Competent Cells Market by End-Use
  - 8.2.3.1 Europe Pharmaceutical & Biotechnology Companies Market by Country
  - 8.2.3.2 Europe Academic & Research Institutes Market by Country
  - 8.2.3.3 Europe Others Market by Country
- 8.2.4 Europe Competent Cells Market by Country
  - 8.2.4.1 Germany Competent Cells Market
    - 8.2.4.1.1 Germany Competent Cells Market by Type
    - 8.2.4.1.2 Germany Competent Cells Market by Application
    - 8.2.4.1.3 Germany Competent Cells Market by End-Use
  - 8.2.4.2 UK Competent Cells Market
    - 8.2.4.2.1 UK Competent Cells Market by Type
    - 8.2.4.2.2 UK Competent Cells Market by Application
    - 8.2.4.2.3 UK Competent Cells Market by End-Use
  - 8.2.4.3 France Competent Cells Market
    - 8.2.4.3.1 France Competent Cells Market by Type
    - 8.2.4.3.2 France Competent Cells Market by Application
    - 8.2.4.3.3 France Competent Cells Market by End-Use
  - 8.2.4.4 Russia Competent Cells Market
    - 8.2.4.4.1 Russia Competent Cells Market by Type
    - 8.2.4.4.2 Russia Competent Cells Market by Application
    - 8.2.4.4.3 Russia Competent Cells Market by End-Use
  - 8.2.4.5 Spain Competent Cells Market
    - 8.2.4.5.1 Spain Competent Cells Market by Type
    - 8.2.4.5.2 Spain Competent Cells Market by Application
    - 8.2.4.5.3 Spain Competent Cells Market by End-Use
  - 8.2.4.6 Italy Competent Cells Market
    - 8.2.4.6.1 Italy Competent Cells Market by Type
    - 8.2.4.6.2 Italy Competent Cells Market by Application
    - 8.2.4.6.3 Italy Competent Cells Market by End-Use
  - 8.2.4.7 Rest of Europe Competent Cells Market
    - 8.2.4.7.1 Rest of Europe Competent Cells Market by Type
    - 8.2.4.7.2 Rest of Europe Competent Cells Market by Application
    - 8.2.4.7.3 Rest of Europe Competent Cells Market by End-Use
8.3 Asia Pacific Competent Cells Market
- 8.3.1 Asia Pacific Competent Cells Market by Type
  - 8.3.1.1 Asia Pacific Chemically Competent Cells Market by Country
  - 8.3.1.2 Asia Pacific Electrocompetent Cells Market by Country
  - 8.3.1.3 Asia Pacific Ultracompetent Cells Market by Country
- 8.3.2 Asia Pacific Competent Cells Market by Application
  - 8.3.2.1 Asia Pacific Cloning Market by Country
  - 8.3.2.2 Asia Pacific Protein Expression Market by Country
  - 8.3.2.3 Asia Pacific Mutagenesis Market by Country
  - 8.3.2.4 Asia Pacific Others Market by Country
- 8.3.3 Asia Pacific Competent Cells Market by End-Use
  - 8.3.3.1 Asia Pacific Pharmaceutical & Biotechnology Companies Market by Country
  - 8.3.3.2 Asia Pacific Academic & Research Institutes Market by Country
  - 8.3.3.3 Asia Pacific Others Market by Country
- 8.3.4 Asia Pacific Competent Cells Market by Country
  - 8.3.4.1 China Competent Cells Market
    - 8.3.4.1.1 China Competent Cells Market by Type
    - 8.3.4.1.2 China Competent Cells Market by Application
    - 8.3.4.1.3 China Competent Cells Market by End-Use
  - 8.3.4.2 Japan Competent Cells Market
    - 8.3.4.2.1 Japan Competent Cells Market by Type
    - 8.3.4.2.2 Japan Competent Cells Market by Application
    - 8.3.4.2.3 Japan Competent Cells Market by End-Use
  - 8.3.4.3 India Competent Cells Market
    - 8.3.4.3.1 India Competent Cells Market by Type
    - 8.3.4.3.2 India Competent Cells Market by Application
    - 8.3.4.3.3 India Competent Cells Market by End-Use
  - 8.3.4.4 South Korea Competent Cells Market
    - 8.3.4.4.1 South Korea Competent Cells Market by Type
    - 8.3.4.4.2 South Korea Competent Cells Market by Application
    - 8.3.4.4.3 South Korea Competent Cells Market by End-Use
  - 8.3.4.5 Australia Competent Cells Market
    - 8.3.4.5.1 Australia Competent Cells Market by Type
    - 8.3.4.5.2 Australia Competent Cells Market by Application
    - 8.3.4.5.3 Australia Competent Cells Market by End-Use
  - 8.3.4.6 Malaysia Competent Cells Market
    - 8.3.4.6.1 Malaysia Competent Cells Market by Type
    - 8.3.4.6.2 Malaysia Competent Cells Market by Application
    - 8.3.4.6.3 Malaysia Competent Cells Market by End-Use
  - 8.3.4.7 Rest of Asia Pacific Competent Cells Market
    - 8.3.4.7.1 Rest of Asia Pacific Competent Cells Market by Type
    - 8.3.4.7.2 Rest of Asia Pacific Competent Cells Market by Application
    - 8.3.4.7.3 Rest of Asia Pacific Competent Cells Market by End-Use
8.4 LAMEA Competent Cells Market
- 8.4.1 LAMEA Competent Cells Market by Type
  - 8.4.1.1 LAMEA Chemically Competent Cells Market by Country
  - 8.4.1.2 LAMEA Electrocompetent Cells Market by Country
  - 8.4.1.3 LAMEA Ultracompetent Cells Market by Country
- 8.4.2 LAMEA Competent Cells Market by Application
  - 8.4.2.1 LAMEA Cloning Market by Country
  - 8.4.2.2 LAMEA Protein Expression Market by Country
  - 8.4.2.3 LAMEA Mutagenesis Market by Country
  - 8.4.2.4 LAMEA Others Market by Country
- 8.4.3 LAMEA Competent Cells Market by End-Use
  - 8.4.3.1 LAMEA Pharmaceutical & Biotechnology Companies Market by Country
  - 8.4.3.2 LAMEA Academic & Research Institutes Market by Country
  - 8.4.3.3 LAMEA Others Market by Country
- 8.4.4 LAMEA Competent Cells Market by Country
  - 8.4.4.1 Brazil Competent Cells Market
    - 8.4.4.1.1 Brazil Competent Cells Market by Type
    - 8.4.4.1.2 Brazil Competent Cells Market by Application
    - 8.4.4.1.3 Brazil Competent Cells Market by End-Use
  - 8.4.4.2 Argentina Competent Cells Market
    - 8.4.4.2.1 Argentina Competent Cells Market by Type
    - 8.4.4.2.2 Argentina Competent Cells Market by Application
    - 8.4.4.2.3 Argentina Competent Cells Market by End-Use
  - 8.4.4.3 UAE Competent Cells Market
    - 8.4.4.3.1 UAE Competent Cells Market by Type
    - 8.4.4.3.2 UAE Competent Cells Market by Application
    - 8.4.4.3.3 UAE Competent Cells Market by End-Use
  - 8.4.4.4 Saudi Arabia Competent Cells Market
    - 8.4.4.4.1 Saudi Arabia Competent Cells Market by Type
    - 8.4.4.4.2 Saudi Arabia Competent Cells Market by Application
    - 8.4.4.4.3 Saudi Arabia Competent Cells Market by End-Use
  - 8.4.4.5 South Africa Competent Cells Market
    - 8.4.4.5.1 South Africa Competent Cells Market by Type
    - 8.4.4.5.2 South Africa Competent Cells Market by Application
    - 8.4.4.5.3 South Africa Competent Cells Market by End-Use
  - 8.4.4.6 Nigeria Competent Cells Market
    - 8.4.4.6.1 Nigeria Competent Cells Market by Type
    - 8.4.4.6.2 Nigeria Competent Cells Market by Application
    - 8.4.4.6.3 Nigeria Competent Cells Market by End-Use
  - 8.4.4.7 Rest of LAMEA Competent Cells Market
    - 8.4.4.7.1 Rest of LAMEA Competent Cells Market by Type
    - 8.4.4.7.2 Rest of LAMEA Competent Cells Market by Application
    - 8.4.4.7.3 Rest of LAMEA Competent Cells Market by End-Use

Chapter 9. Company Profiles

9.1 Thermo Fisher Scientific, Inc.
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Segmental and Regional Analysis
- 9.1.4 Research & Development Expenses
- 9.1.5 Recent strategies and developments:
  - 9.1.5.1 Partnerships, Collaborations, and Agreements:
  - 9.1.5.2 Product Launches and Product Expansions:
  - 9.1.5.3 Geographical Expansions:
- 9.1.6 SWOT Analysis
9.2 Merck KGaA
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Segmental and Regional Analysis
- 9.2.4 Research & Development Expense
- 9.2.5 Recent strategies and developments:
  - 9.2.5.1 Partnerships, Collaborations, and Agreements:
- 9.2.6 SWOT Analysis
9.3 Agilent Technologies, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Segmental and Regional Analysis
- 9.3.4 Research & Development Expense
- 9.3.5 Recent strategies and developments:
  - 9.3.5.1 Trail and Approvals:
- 9.3.6 SWOT Analysis
9.4 Bio-Rad laboratories, Inc.
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expenses
- 9.4.5 SWOT Analysis
9.5 Promega Corporation
- 9.5.1 Company Overview
- 9.5.2 Recent strategies and developments:
  - 9.5.2.1 Partnerships, Collaborations, and Agreements:
- 9.5.3 SWOT Analysis
9.6 New England Biolabs, Inc.
- 9.6.1 Company Overview
- 9.6.2 SWOT Analysis
9.7 Qiagen N.V.
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Regional Analysis
- 9.7.4 Research & Development Expenses
- 9.7.5 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Segmental and Regional Analysis
- 9.8.4 Research & Development Expense
- 9.8.5 SWOT Analysis
9.9 Takara Bio Inc. (Takara Holdings Inc.)
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Segmental and Regional Analysis
- 9.9.4 Research & Development Expenses
9.10. Lonza Group Ltd. (Capsugel)
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Segmental and Regional Analysis
- 9.10.4 Research & Development Expenses
- 9.10.5 SWOT Analysis

한글목차

목차

제1장 시장 범위와 조사 방법

제2장 시장 요람

제3장 시장 개요

제4장 컴피턴트 세포 시장에서 전개되는 전략

제5장 세계의 컴피턴트 세포 시장 : 유형별

제6장 세계의 컴피턴트 세포 시장 : 용도별

제7장 세계의 컴피턴트 세포 시장 : 최종 용도별

제8장 세계의 컴피턴트 세포 시장 : 지역별